title: Plasma Autoantibodies Associated with Basal-like Breast Cancers.
abstract: BACKGROUND
  Basal-like breast cancer (BLBC) is a rare aggressive subtype that is less likely to be detected through mammographic screening. Identification of circulating markers associated with BLBC could have promise in detecting and managing this deadly disease.
  
  
  METHODS
  Using samples from the Polish Breast Cancer study, a high-quality population-based case-control study of breast cancer, we screened 10,000 antigens on protein arrays using 45 BLBC patients and 45 controls, and identified 748 promising plasma autoantibodies (AAbs) associated with BLBC. ELISA assays of promising markers were performed on a total of 145 BLBC cases and 145 age-matched controls. Sensitivities at 98% specificity were calculated and a BLBC classifier was constructed.
  
  
  RESULTS
  We identified 13 AAbs (CTAG1B, CTAG2, TP53, RNF216, PPHLN1, PIP4K2C, ZBTB16, TAS2R8, WBP2NL, DOK2, PSRC1, MN1, TRIM21) that distinguished BLBC from controls with 33% sensitivity and 98% specificity. We also discovered a strong association of TP53 AAb with its protein expression (P = 0.009) in BLBC patients. In addition, MN1 and TP53 AAbs were associated with worse survival [MN1 AAb marker HR = 2.25, 95% confidence interval (CI), 1.03-4.91; P = 0.04; TP53, HR = 2.02, 95% CI, 1.06-3.85; P = 0.03]. We found limited evidence that AAb levels differed by demographic characteristics.
  
  
  CONCLUSIONS
  These AAbs warrant further investigation in clinical studies to determine their value for further understanding the biology of BLBC and possible detection.
  
  
  CONCLUSIONS
  Our study identifies 13 AAb markers associated specifically with BLBC and may improve detection or management of this deadly disease.
authors.affiliation: Biodesign Institute, Arizona State University, Tempe, Arizona.
authors.forename: Jie
authors.initials: J
authors.lastname: Wang
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
authors.forename: Jonine D
authors.initials: JD
authors.lastname: Figueroa
authors.affiliation: Biodesign Institute, Arizona State University, Tempe, Arizona.
authors.forename: Garrick
authors.initials: G
authors.lastname: Wallstrom
authors.affiliation: Biodesign Institute, Arizona State University, Tempe, Arizona.
authors.forename: Kristi
authors.initials: K
authors.lastname: Barker
authors.affiliation: Biodesign Institute, Arizona State University, Tempe, Arizona.
authors.forename: Jin G
authors.initials: JG
authors.lastname: Park
authors.affiliation: Biodesign Institute, Arizona State University, Tempe, Arizona.
authors.forename: Gokhan
authors.initials: G
authors.lastname: Demirkan
authors.affiliation: M. Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland.
authors.forename: Jolanta
authors.initials: J
authors.lastname: Lissowska
authors.affiliation: Biodesign Institute, Arizona State University, Tempe, Arizona.
authors.forename: Karen S
authors.initials: KS
authors.lastname: Anderson
authors.affiliation: Biodesign Institute, Arizona State University, Tempe, Arizona. Joshua.LaBaer@asu.edu Ji.Qiu@asu.edu.
authors.forename: Ji
authors.initials: J
authors.lastname: Qiu
authors.affiliation: Biodesign Institute, Arizona State University, Tempe, Arizona. Joshua.LaBaer@asu.edu Ji.Qiu@asu.edu.
authors.forename: Joshua
authors.initials: J
authors.lastname: LaBaer
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000276:immunology; D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D001323:Autoantibodies / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000737:chemistry / Q000276:immunology* / Q000473:pathology; D002352:Carrier Proteins / Q000276:immunology; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D051741:Kruppel-Like Transcription Factors / Q000276:immunology; D008565:Membrane Proteins / Q000276:immunology; D008875:Middle Aged; D009687:Nuclear Proteins / Q000276:immunology; D010750:Phosphoproteins / Q000276:immunology; D011044:Poland; D000075722:Promyelocytic Leukemia Zinc Finger Protein; D040081:Protein Array Analysis; D012333:RNA, Messenger / Q000097:blood*; D011956:Receptors, Cell Surface / Q000276:immunology; D043562:Receptors, G-Protein-Coupled; D012261:Ribonucleoproteins / Q000276:immunology; D029589:Seminal Plasma Proteins / Q000276:immunology; D012680:Sensitivity and Specificity; D015996:Survival Rate; D015534:Trans-Activators; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000235:genetics / Q000276:immunology*; D025521:Tumor Suppressor Proteins / Q000276:immunology; D044767:Ubiquitin-Protein Ligases / Q000276:immunology; D000099207:SS-A Antigen
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D001323:Autoantibodies; D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D051741:Kruppel-Like Transcription Factors; D008565:Membrane Proteins; D009687:Nuclear Proteins; D010750:Phosphoproteins; D000075722:Promyelocytic Leukemia Zinc Finger Protein; D012333:RNA, Messenger; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D012261:Ribonucleoproteins; D029589:Seminal Plasma Proteins; D015534:Trans-Activators; D016159:Tumor Suppressor Protein p53; D025521:Tumor Suppressor Proteins; D044767:Ubiquitin-Protein Ligases; D000099207:SS-A Antigen; C104948:CTAG1B protein, human; C510162:CTAG2 protein, human; C115089:DOK2 protein, human; C506524:MN1 protein, human; C478775:PPHLN1 protein, human; C485740:PSRC1 protein, human; C562003:TAS2R8 protein, human; C495901:TP53 protein, human; C519840:WBP2NL protein, human; C092037:ZBTB16 protein, human; C458527:RNF216 protein, human